“Flu, COVID and RSV: How to vaccinate?” symposium at Options XI
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
|
ESWI Airborne: Meet the Members
A geriatrician's insight into reducing the burden of disease in older adults
Who is at an increased risk of adverse effects from an RSV infection? What is the burden of disease and what should be done to alleviate the risk and increase awareness?
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
|
ESWI Airborne: Meet the Members
Walk the talk on immunisation
With a wealth of experience, Professor of Epidemiology and former Minister of Health, ESWI Board Member Roman Prymula gives a personal testimony of the COVID-19 pandemic and the different perspectives of politics vs science when it comes to health policy.
International community will gather in Brussels to discuss pandemic preparedness
Next Tuesday 21 June, the European Scientific Working group on Influenza (ESWI) will host a summit on the continuing pandemic threat posed by respiratory viruses, entitled “Pandemic Preparedness: Where Science and Policy Meet”.
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model
In this human infection challenge pilot study, adults aged 18–55 years and 60–75 years were assessed for enrolment using protocol-defined inclusion and exclusion criteria.
|
8th influenza conference 2021
8th ESWI Influenza Conference
|
8th influenza conference 2021
8th ESWI Influenza Conference
|
8th influenza conference 2021
8th ESWI Influenza Conference